Yes Tony, It has been a momentous year of development as NNZ-2566 has moved beyond TBI into the arena of neuro-developmental disorders. We now occupy a space where few biotech companies have the courage to operate which is why it remains an area of high unmet need.
If we didn't see what was coming, further surprises may be ahead. Success in one trial will open up the most exciting opportunities across the whole spectrum of autism spectrum disorders and cognitive impairment.
Virani remarks that "[Roche] remain very open across the value chain all the way from promising approaches in early research but also programs that have shown some signal in related conditions such as Fragile X and Rett Syndrome."
Roche will be but one Big Pharma attracted by the opportunity to partner an emerging biotech with an exciting evolving science.
Regards,
Wayne.
NEU Price at posting:
3.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)